{"id":"W2505393039","doi":"10.1007/s00345-016-1903-6","title":"Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms","year":2016,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; GlaxoSmithKline Australia; Novartis; Les Laboratories Pierre Fabre; Bayer; AstraZeneca; Merck; Novartis Pharma; Roche; Astellas Pharma US; Pfizer","keywords":"Medicine; Cabozantinib; Axitinib; Nivolumab; Everolimus; Clinical trial; Sunitinib; Intensive care medicine; Oncology; Kidney cancer; Second line treatment; Internal medicine; Tyrosine-kinase inhibitor; Cancer; Renal cell carcinoma; Chemotherapy; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002615314,0.0002918707,0.0008219875,0.0003621422,0.00006313391,0.00000876479,0.0001160224,0.00006711297,0.001325485],"category_scores_gemma":[0.00003162892,0.0001624281,0.0004196297,0.0001203583,0.000137066,0.00003886799,0.0000219108,0.0001338858,0.00002763452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000416449,"about_ca_system_score_gemma":0.0003809702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002391249,"about_ca_topic_score_gemma":0.0001227023,"domain_scores_codex":[0.998123,0.0001413644,0.0007597348,0.0002808693,0.0002351726,0.0004598872],"domain_scores_gemma":[0.9979007,0.0006178211,0.0005751454,0.0002779764,0.0002782723,0.000350145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02612038,0.004132095,0.004210429,0.0002630636,0.002644106,0.008152621,0.001192818,0.0002153403,0.6992916,0.000129432,0.06544375,0.1882043],"study_design_scores_gemma":[0.0395874,0.03346264,0.001538729,0.0001050733,0.002674134,0.003466219,0.0001556346,0.0002175511,0.3277764,0.0004311927,0.5901811,0.0004038794],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9514683,0.02458301,0.001525666,0.01709413,0.001069496,0.0009755352,0.0001177631,0.00003060956,0.003135528],"genre_scores_gemma":[0.9701412,0.001213992,0.00748525,0.0008961408,0.0006581616,0.00005142845,0.000005197888,0.00005472716,0.01949388],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5247374,"threshold_uncertainty_score":0.9995874,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04549877941455106,"score_gpt":0.3060013331278901,"score_spread":0.260502553713339,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}